| Literature DB >> 28573109 |
Jaya D Chidambaram1, Shichina Kannambath2, Palepu Srikanthi3, Manisha Shah3,4, Prajna Lalitha3,4, Shanmugam Elakkiya4, Julien Bauer5, Namperumalsamy V Prajna3,4, Martin J Holland1, Matthew J Burton1.
Abstract
Microbial keratitis (MK) is a major cause of blindness worldwide. Despite adequate antimicrobial treatment, tissue damage can ensue. We compared the human corneal transcriptional profile in late stage MK to normal corneal tissue to identify pathways involved in pathogenesis. Total RNA from MK tissue and normal cadaver corneas was used to determine transcriptome profiles with Illumina HumanHT-12 v4 beadchips. We performed differential expression and network analysis of genes in bacterial keratitis (BK) and fungal keratitis (FK) compared with control (C) samples. Results were validated by RTqPCR for 45 genes in an independent series of 183 MK patients. For the microarray transcriptome analysis, 27 samples were used: 12 controls, 7 BK culture positive for Streptococcus pneumoniae (n = 6), Pseudomonas aeruginosa (n = 1), and 8 FK, culture positive for Fusarium sp. (n = 5), Aspergillus sp. (n = 2), or Lasiodiplodia sp. (n = 1). There were 185 unique differentially expressed genes in BK, 50 in FK, and 339 common to both [i.e., genes with fold-change (FC) < -4 or ≥4 and false discovery rate (FDR) adjusted P < 0.05]. MMP9 had the highest FC in BK (91 FC, adj p = 3.64 E-12) and FK (FC 64, adj. p = 6.10 E-11), along with other MMPs (MMP1, MMP7, MMP10, MMP12), pro-inflammatory cytokines (IL1B, TNF), and PRRs (TLR2, TLR4). HIF1A and its induced genes were upregulated uniquely in BK. Immune/defense response and extracellular matrix terms were the most enriched Gene Ontology terms in both BK and FK. In the network analysis, chemokines were prominent for FK, and actin filament reorganization for BK. Microarray and RTqPCR results were highly correlated for the same samples tested with both assays, and with the larger RTqPCR series. In conclusion, we found a great deal of overlap in the gene expression profile of late stage BK and FK, however genes unique to fungal infection highlighted a corneal epithelial wound healing response and for bacterial infection the prominence of HIF1A-induced genes. These sets of genes may provide new targets for future research into therapeutic agents.Entities:
Keywords: aspergillus; bacteria; corneal ulcer; fungi; fusarium; keratitis; streptococcus; transcriptome
Mesh:
Substances:
Year: 2017 PMID: 28573109 PMCID: PMC5435826 DOI: 10.3389/fcimb.2017.00193
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Summary of clinical and sociodemographic data of study participants.
| Gender, No. Male (%) | 7 (58%) | 7 (100%) | 13 (72%) | 0.12 | 4 (50%) | 105 (64%) | 0.44 | 0.03 | 0.47 |
| Age, median (IQR), years | 82 (76.5–90) | 67 (60–75) | 55 (35–62) | 0.02 | 52.5 (43–62.5) | 50 (36.5–58) | 0.44 | 0.04 | 0.41 |
| Symptom duration, median (range), days | – | 15 (7–20) | 10 (2–90) | 0.19 | 14.5 (2–43) | 7 (1–90) | 0.12 | 1.00 | 0.12 |
| Uncorrected visual acuity | – | 1.9 (1.8–1.9) | 1.7 (1.7–1.8) | 0.01 | 1.85 (1.8–1.9) | 1.8 (0.56–1.8) | <0.01 | 0.62 | 0.86 |
| Median stromal infiltrate size | – | 7.0 (5.7–8.5) | 3.8 (3.2–5.1) | <0.01 | 5.8 (4.3–9.2) | 4.4 (3.5—5.5) | 0.04 | 0.68 | 0.58 |
| Perforation | – | 7 (100%) | 1 (5%) | 0.01 | 3 (38%) | 19 (11%) | <0.01 | 0.01 | 0.44 |
Visual Acuity measured in logMAR units:>1.0, unable to read any letters on chart; 1.8, able to count fingers only; 1.9, able to see hand movements only; 2.0, perception of light only.
Stromal infiltrate size calculated as geometric mean of longest stromal infiltrate diameter and its perpendicular measurement (mm).
All p-values generated by comparing microarray study participants vs. validation cohort, within bacterial or fungal keratitis groups.
Microbiological results of corneal ulcers.
| 6 (40%) | 8 (4.4%) | |
| 1 (6.7%) | 3 (1.6%) | |
| – | 3 (1.6%) | |
| – | 2 (1.1%) | |
| – | 1 (0.5%) | |
| – | 1 (0.5%) | |
| 5 (33.3%) | 69 (37.7%) | |
| 1 (6.7%) | 25 (13.7%) | |
| 1 (6.7%) | 2 (1.1%) | |
| – | 4 (2.2%) | |
| 1 (6.7%) | 2 (1.1%) | |
| – | 5 (2.7%) | |
| – | 5 (2.7%) | |
| – | 1 (0.5%) | |
| – | 1 (0.5%) | |
| – | 1 (0.5%) | |
| Unidentified dematiaceous fungus | – | 9 (4.9%) |
| Unidentified hyaline fungus | – | 13 (7.1%) |
| Microscopy positive (no growth) | – | 28 (15.3%) |
Summary of expressed genes in microarray pairwise comparisons (FK, Fungal Keratitis; BK, Bacterial Keratitis; C, Controls).
| No. of expressed genes | 17,753 | 17,434 | 17,120 |
| 6,414 | 7,825 | 18 | |
| 4,119 | 5,384 | 0 | |
| No. of differentially expressed genes | 389 | 524 | 0 |
| Up-regulated | 291 | 361 | 0 |
| Down-regulated | 98 | 163 | 0 |
Genes were considered differentially expressed if FDR-adjusted p-value < 0.05 and fold change was < –4 or ≥4.
Figure 1Plot of hierarchical clustering of log. (Color scale red = log2FC of 8, green log2FC of 14). Bacterial and fungal ulcer samples are interspersed, but normal control tissue samples cluster together in the hierarchical cluster plot of the differentially expressed genes only. The whole-genome level expression profile of raw data for all samples is shown in Figure S1.
Top three most significantly enriched biological process Gene Ontology (GO) terms for microarray pairwise comparisons.
| Genes common to both bacterial and fungal keratitis compared to control tissue | GO:0006955: immune response | 4.6 | 5.37 E-50 |
| GO:0006952: defense response | 4.3 | 2.38 E -42 | |
| GO:0002682: regulation of immune system process | 4.4 | 9.68 E-19 | |
| Genes unique to bacterial keratitis | GO:0006954: inflammatory response | 6.3 | 3.63 E-13 |
| GO: 0002682: regulation of immune system process | 5.3 | 6.89 E-13 | |
| GO:0001816: cytokine production | 8.7 | 1.82 E-12 | |
| Genes unique to fungal keratitis | GO:1901700: response to oxygen-containing compound | 4.3 | 2.9 E-06 |
| GO:0000302: response to reactive oxygen species | 11.9 | 1.2 E-04 | |
| GO:0009605: response to external stimulus | 3.0 | 1.5 E-04 |
Analyses performed in DAVID v6.8 (all p-values unadjusted).
RTqPCR differential expression analysis results using RNA from microarray study participants.
| Immune response | 5284.76 | 1.15E-08 | 1458.86 | 2.97E-07 | 3.62 | 9.32E-01 | |
| 209.81 | 3.41E-07 | 151.09 | 1.34E-06 | 1.39 | 9.32E-01 | ||
| 93.32 | 3.32E-04 | 41.04 | 2.43E-03 | 2.27 | 9.32E-01 | ||
| 26.57 | 3.82E-03 | 118.69 | 1.09E-04 | 0.22 | 9.32E-01 | ||
| 22.06 | 1.02E-03 | 8.86 | 1.48E-02 | 2.49 | 9.32E-01 | ||
| 624.37 | 1.22E-05 | 191.25 | 1.54E-04 | 3.26 | 9.32E-01 | ||
| 240.14 | 3.22E-05 | 118.04 | 1.59E-04 | 2.03 | 9.32E-01 | ||
| 17.36 | 4.82E-04 | 9.80 | 3.96E-03 | 1.77 | 9.32E-01 | ||
| 8.20 | 2.36E-02 | 1.30 | 7.82E-01 | 6.33 | 9.32E-01 | ||
| 7.17 | 3.88E-02 | 9.48 | 1.87E-02 | 0.76 | 9.32E-01 | ||
| 2.01 | 4.46E-01 | 1.18 | 8.47E-01 | 1.70 | 9.32E-01 | ||
| 0.93 | 9.05E-01 | 0.76 | 6.80E-01 | 1.23 | 9.32E-01 | ||
| 0.55 | 4.77E-01 | 3.20 | 1.72E-01 | 0.17 | 9.32E-01 | ||
| 136.48 | 2.77E-06 | 130.90 | 3.07E-06 | 1.04 | 9.95E-01 | ||
| 0.00 | 1.15E-08 | 0.02 | 1.54E-05 | 0.10 | 4.60E-01 | ||
| 904.84 | 3.88E-08 | 259.07 | 1.34E-06 | 3.49 | 9.32E-01 | ||
| PRRs | 79.40 | 8.36E-08 | 66.52 | 2.97E-07 | 1.19 | 9.32E-01 | |
| 1.83 | 3.36E-01 | 2.19 | 2.09E-01 | 0.84 | 9.32E-01 | ||
| 49.67 | 1.66E-06 | 54.44 | 1.34E-06 | 0.91 | 9.76E-01 | ||
| 334.06 | 2.99E-08 | 271.71 | 1.32E-07 | 1.23 | 9.32E-01 | ||
| 17.83 | 2.03E-04 | 13.38 | 6.31E-04 | 1.33 | 9.32E-01 | ||
| 0.09 | 2.33E-03 | 0.12 | 6.26E-03 | 0.76 | 9.32E-01 | ||
| 9.11 | 1.64E-03 | 9.06 | 1.80E-03 | 1.00 | 9.95E-01 | ||
| 27.73 | 9.41E-05 | 9.84 | 3.96E-03 | 2.82 | 9.32E-01 | ||
| 159.96 | 2.73E-07 | 163.95 | 3.95E-07 | 0.98 | 9.95E-01 | ||
| 37.29 | 6.68E-05 | 19.28 | 6.17E-04 | 1.93 | 9.32E-01 | ||
| ECM | 4.91 | 9.18E-02 | 16.45 | 4.84E-03 | 0.30 | 9.32E-01 | |
| 10.64 | 2.06E-02 | 19.80 | 4.36E-03 | 0.54 | 9.32E-01 | ||
| 0.00 | 2.26E-05 | 0.01 | 1.52E-04 | 0.44 | 9.32E-01 | ||
| 29.45 | 3.59E-03 | 94.62 | 2.15E-04 | 0.31 | 9.32E-01 | ||
| 0.04 | 6.68E-05 | 0.04 | 4.97E-05 | 1.09 | 9.76E-01 | ||
| MMPs | 93.57 | 2.77E-06 | 110.98 | 1.70E-06 | 0.84 | 9.45E-01 | |
| 21.66 | 4.82E-04 | 10.67 | 4.90E-03 | 2.03 | 9.32E-01 | ||
| 59.43 | 1.33E-04 | 110.09 | 2.58E-05 | 0.54 | 9.32E-01 | ||
| 0.22 | 6.19E-02 | 0.33 | 1.68E-01 | 0.68 | 9.32E-01 | ||
| 41.29 | 1.78E-04 | 51.95 | 9.64E-05 | 0.79 | 9.32E-01 | ||
| 2117.89 | 7.16E-10 | 4151.54 | 8.34E-11 | 0.51 | 9.32E-01 | ||
| 34.91 | 4.58E-05 | 70.56 | 3.18E-06 | 0.49 | 9.32E-01 | ||
| Anti-microbial peptides | 3551.44 | 9.58E-08 | 2181.29 | 3.95E-07 | 1.63 | 9.32E-01 | |
| 127.46 | 5.71E-04 | 427.84 | 4.97E-05 | 0.30 | 9.32E-01 | ||
| 37.40 | 1.20E-04 | 60.60 | 2.58E-05 | 0.62 | 9.32E-01 | ||
| 45.05 | 1.92E-03 | 84.92 | 4.65E-04 | 0.53 | 9.32E-01 | ||
| Peptidase inhibitors | 38.90 | 5.38E-06 | 46.80 | 2.67E-06 | 0.83 | 9.32E-01 | |
| 3.98 | 5.34E-02 | 6.61 | 9.83E-03 | 0.60 | 9.32E-01 | ||
| 0.11 | 3.66E-03 | 0.29 | 8.72E-02 | 0.39 | 9.32E-01 | ||
BK, Bacterial Keratitis; FK, Fungal keratitis; C, Controls; PRRs, Pattern Recognition Receptors; ECM, Extra-Cellular Matrix; MMPs, Matrix Metallopeptidases.
RTqPCR differential expression analysis results using samples from the validation cohort of microbial keratitis patients.
| 2792.89 | 3.21E-16 | 1564.99 | 9.69E-21 | 1.78 | 0.947 | ||
| 205.85 | 7.50E-06 | 196.07 | 3.68E-08 | 1.05 | 0.957 | ||
| 1320.91 | 3.78E-16 | 656.98 | 8.32E-20 | 2.01 | 0.947 | ||
| 147.23 | 1.95E-07 | 180.04 | 2.92E-11 | 0.82 | 0.947 | ||
| 109.8 | 2.93E-11 | 84.25 | 8.61E-15 | 1.3 | 0.947 | ||
| 1035.87 | 2.15E-14 | 1272.22 | 2.15E-21 | 0.81 | 0.947 | ||
| 959.19 | 1.44E-13 | 1296.59 | 1.32E-20 | 0.74 | 0.947 | ||
| 65.29 | 1.98E-06 | 74.92 | 1.36E-09 | 0.87 | 0.947 | ||
| 201.64 | 1.18E-04 | 218.43 | 1.27E-06 | 0.92 | 0.957 | ||
| 1238.8 | 3.84E-14 | 1665.71 | 2.15E-21 | 0.74 | 0.947 | ||
| 138.09 | 8.47E-04 | 129.84 | 4.11E-05 | 1.06 | 0.957 | ||
| 27.5 | 2.84E-05 | 19.34 | 2.76E-06 | 1.42 | 0.947 | ||
| 190.28 | 3.71E-05 | 182.04 | 3.73E-07 | 1.05 | 0.957 | ||
| 206.05 | 8.59E-10 | 423.63 | 4.60E-17 | 0.49 | 0.947 | ||
| 0.05 | 6.46E-03 | 0.03 | 1.32E-04 | 1.46 | 0.947 | ||
| 1167.59 | 1.29E-13 | 1591.01 | 9.69E-21 | 0.73 | 0.947 | ||
| PRRs | 135.1 | 1.03E-09 | 311.48 | 1.20E-17 | 0.43 | 0.947 | |
| 19.42 | 1.26E-04 | 24.77 | 3.23E-07 | 0.78 | 0.947 | ||
| 77.22 | 4.24E-09 | 145.47 | 4.32E-16 | 0.53 | 0.947 | ||
| 268.45 | 5.35E-10 | 465.36 | 1.40E-16 | 0.58 | 0.947 | ||
| 161.68 | 1.22E-10 | 253.77 | 2.15E-17 | 0.64 | 0.947 | ||
| 1.64 | 6.16E-01 | 0.93 | 9.28E-01 | 1.76 | 0.947 | ||
| 270.16 | 1.68E-12 | 497.91 | 9.69E-21 | 0.54 | 0.947 | ||
| 76.09 | 7.50E-06 | 106.71 | 2.72E-09 | 0.71 | 0.947 | ||
| 398.21 | 1.38E-11 | 251.09 | 9.53E-15 | 1.59 | 0.947 | ||
| 35.68 | 3.72E-05 | 48.95 | 3.22E-08 | 0.73 | 0.947 | ||
| ECM | 6.66 | 2.91E-02 | 3.21 | 9.56E-02 | 2.07 | 0.947 | |
| 61.06 | 5.24E-05 | 47.83 | 2.20E-06 | 1.28 | 0.947 | ||
| 0.03 | 1.28E-02 | 0.04 | 3.57E-03 | 0.8 | 0.947 | ||
| 2101.97 | 6.00E-21 | 2937.8 | 3.19E-31 | 0.72 | 0.947 | ||
| 1.8 | 5.27E-01 | 0.74 | 6.80E-01 | 2.44 | 0.947 | ||
| MMPs | 536.49 | 1.39E-12 | 565.54 | 3.04E-18 | 0.95 | 0.957 | |
| 459.9 | 2.93E-11 | 405.57 | 1.17E-15 | 1.13 | 0.947 | ||
| 2791.89 | 1.07E-08 | 717.96 | 3.14E-09 | 3.89 | 0.947 | ||
| 12.71 | 1.70E-02 | 8.39 | 1.28E-02 | 1.52 | 0.947 | ||
| 335.79 | 7.50E-09 | 296.06 | 3.26E-12 | 1.13 | 0.947 | ||
| 7754.12 | 5.23E-22 | 11661.09 | 8.82E-33 | 0.66 | 0.947 | ||
| 156.56 | 7.64E-08 | 284.19 | 2.46E-13 | 0.55 | 0.947 | ||
| Anti-microbial peptides | 4787.64 | 6.43E-23 | 5666.71 | 8.82E-33 | 0.84 | 0.947 | |
| 7119.6 | 1.44E-13 | 3891.02 | 1.90E-17 | 1.83 | 0.947 | ||
| 831.43 | 6.43E-23 | 921.41 | 8.82E-33 | 0.9 | 0.947 | ||
| 1421.62 | 6.51E-14 | 1208.72 | 2.57E-19 | 1.18 | 0.947 | ||
| Peptidase inhibitors | 134.64 | 1.29E-10 | 311.83 | 2.57E-19 | 0.43 | 0.947 | |
| 3.81 | 1.23E-02 | 4.4 | 5.26E-04 | 0.87 | 0.947 | ||
| 1.09 | 9.26E-01 | 0.59 | 4.97E-01 | 1.84 | 0.947 | ||
BK, Bacterial Keratitis; FK, Fungal keratitis; C, Controls; PRRs, Pattern Recognition Receptors; ECM, Extra-Cellular Matrix; MMPs, Matrix Metallopeptidases.
Figure 2Scatter plots showing log fungal keratitis and (B) bacterial keratitis vs. controls (Spearman's rho 0.9, p < 0.0001 for both).